New tools for exploring immunogenic neoepitopes in cancer.
Identifying neoepitopes that elicit an adaptive immune response is a major bottleneck to developing personalized cancer immunotherapy therapies. Experimental validation of candidate neoepitopes is extremely resource intensive, and the vast majority of candidates are non-immunogenic, making their identification a needle-in-a-haystack problem. To address this challenge, we developed BigMHC, a deep learning method that predicts MHC-I epitopes and identifies immunogenic neoepitopes with high precision.
We develop computational models to interpret and predict the impact of individual variation in the genome, transcriptome, and proteome. The models are being applied to cancer genomics, unclassified variants in Mendelian disease genes, and complex disease genetics. In collaboration with clinicians, pathologists, and experimental biologists, we aim to make significant improvements in individualized medicine within the next five years.
Lab Members and More Lab Info »
Shao, XM et al. (2022) Ann Oncol. Jul;33(7):728-738 Article
Zheng, L et al. (2022) Bioinformatics Jun 1:btac367 Article
Pagel K et al. (2020) Journal of Clinical Oncology CCI. Mar;4:310-317 Article